1. Inicio
  2. Publicaciones
  3. MUC1 Aptamer-Capped Mesoporous Silica Nanoparticles for Navitoclax Resistance Overcoming in Triple-Negative Breast Cancer

MUC1 Aptamer-Capped Mesoporous Silica Nanoparticles for Navitoclax Resistance Overcoming in Triple-Negative Breast Cancer

Fecha de publicación: Fecha Ahead of Print:

Autores de CIPF

  • Gema Vivo Llorca

    Autor

  • Alba Garcia Fernandez

    Autor

  • Félix Sancenón Galarza

    Autor

  • Ramón Martínez Mañez

    Autor

Participantes ajenos a CIPF

  • Candela-Noguera, V
  • Alfonso, M

Grupos de Investigación

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. In the last years, navitoclax has emerged as a possible treatment for TNBC. Nevertheless, rapid navitoclax resistance onset has been observed thorough Mcl-1 overexpression. As a strategy to overcome Mcl-1-mediated resistance, herein we present a controlled drug co-delivery system based on mesoporous silica nanoparticles (MSNs) targeted to TNBC cells. The nanocarrier is loaded with navitoclax and the Mcl-1 inhibitor S63845 and capped with a MUC1-targeting aptamer (apMUC1-MSNs(Nav/S63845)). The apMUC1-capped nanoparticles effectively target TNBC cell lines and successfully induce apoptosis, overcoming navitoclax resistance. Moreover, navitoclax encapsulation protects platelets against apoptosis. These results point apMUC1-gated MSNs as suitable BH3 mimetics nanocarriers in the targeted treatment of MUC1-expressing TNBC.

Datos de la publicación

ISSN/ISSNe:
0947-6539, 1521-3765

CHEMISTRY-A EUROPEAN JOURNAL  WILEY-V C H VERLAG GMBH

Tipo:
Article
Páginas:
16318-16327
PubMed:
32735063

Citas Recibidas en Web of Science: 21

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • apoptosis; cancer; drug delivery; nanoparticles; targeting

Campos de Estudio

Proyectos asociados

Ensuring long-term sustainability of excellence in chemical biology within Europe and beyond

Investigador Principal: MARIA JESUS VICENT DOCON

COMMISSION OF EUROPEAN COMMUNITIES . 2019

Red de Transtornos Adictivos

Investigador Principal: CONSUELO GUERRI SIRERA

INSTITUTO DE SALUD CARLOS III . 2017

Descifrando y modulando el interactoma transmembrana de las proteínas Bcl-2 como diana antitumoral

Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD

MINISTERIO DE ECON. Y COMPET. . 2018

MEMBDEATH: Muerte celular y membranas: un nuevo nicho en la lucha contra el cáncer. Colab con la UV, no recibimos financiación

Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD

CONSELLERIA DE EDUCACION . 2019

Compartir